Spine biologics market to reach $2.5B value by 2022: 5 takeaways

Written by Mackenzie Garrity | July 18, 2017 | Print  |


The global spine biologics market is predicted to exceed more than $2.5 billion by 2022 with a growth rate of 4.4 percent, Finance Wire reports.

Here are five takeaways:


1. Driving factors of the market are innovative technological advancements, advantages of biologics, demand for minimally invasive surgery and new treatment techniques and devices.


2. Potential restraints include unfavorable reimbursement policies, high costs, lack of professional experience and ethical issues associated to bone grafting procedures.


3. DePuy Spine, Medtronic, Stryker, Smith & Nephew, NuVasive and Zimmer Spine are key influencers of the market.


4. Surgeries analyzed by the market include anterior cervical discectomy and fusion, anterior lumbar interbody fusion, transforaminal lumbar interbody fusion and lateral lumber interbody fusion.


5. The biologics market covers bone graft substitutes, platelet rich plasma, bong grafts and bone marrow aspirate concentrate therapy.


More articles on spine:
AANS recognizes Dr. Victor Kareh with Continuing Education Award in Neurosurgery: 6 highlights
Spine surgeon joins Novant Health: 3 insights
CMS proposes 2 new spine codes for the ASC payable list

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months